Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2022
August 2022, Vol 13, No 4 Online Only
August 2022, Vol 13, No 4 Online Only
ASCO President Stresses the Importance of Innovation for Advancing Equitable Cancer Care
By
Wayne Kuznar
Healthcare Equity
August 2022, Vol 13, No 4 Online Only
The theme for the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting selected by 2021-2022 ASCO President Everett E. Vokes, MD, John E. Ultmann Professor of Medicine, and Chair, Department of Medicine, University of Chicago Duchossois Center for Advanced Medicine, Hyde Park, was advancing equitable cancer care through innovation.
Read More
Trastuzumab Deruxtecan Is a New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
By
Wayne Kuznar
ASCO 2022 Highlights
,
Breast Cancer
August 2022, Vol 13, No 4 Online Only
Targeting
HER2
with the antibody–drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) provided clinically meaningful benefits for patients with
HER2
-low metastatic breast cancer, according to findings presented at the 2022 American Society of Clinical Oncology Annual Meeting.
Read More
Sotorasib Elicits Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
By
Phoebe Starr
Lung Cancer
August 2022, Vol 13, No 4 Online Only
Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–small-cell lung cancer (NSCLC) with
KRAS
p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial.
Read More
First-Line Treatment with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer
By
Phoebe Starr
ASCO 2022 Highlights
,
Rectal Cancer
August 2022, Vol 13, No 4 Online Only
First-line treatment with dostarlimab-gxly (Jemperli), a PD-1 inhibitor, achieved complete responses (CRs) in 100% of a subset of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, sparing them surgery, chemotherapy, and radiation, as of the latest follow-up.
Read More
Black Patients with Cancer and COVID-19 More Likely to Have Treatment Disruptions Than White Patients
By
Phoebe Starr
ASCO 2022 Highlights
August 2022, Vol 13, No 4 Online Only
According to data from the American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry, black or African-American patients with cancer and COVID-19 were more likely than non-Hispanic white patients to experience delays or disruptions in cancer treatment during the pandemic.
Read More
Second-Line Treatment with Sacituzumab plus Pembrolizumab Shows Promising Activity in Metastatic Urothelial Cancer
By
Phoebe Starr
Genitourinary Cancers
August 2022, Vol 13, No 4 Online Only
The addition of sacituzumab govitecan (Trodelvy), an antibody–drug conjugate, to the PD-1 inhibitor pembrolizumab (Keytruda) showed encouraging antitumor activity in checkpoint inhibitor–naïve patients with metastatic urothelial cancer, according to an analysis of the results of cohort 3 from the phase 2 TROPHY-U-01 clinical trial.
Read More
Acalabrutinib Shows Promise in Patients with MZL
By
Phoebe Starr
ASCO 2022 Highlights
August 2022, Vol 13, No 4 Online Only
Treatment with acalabrutinib (Calquence) elicited a complete or partial response in more than 50% of patients with relapsed or refractory marginal zone lymphoma (MZL), according to interim results of a phase 2 study.
Read More
Better Communication Between Oncologists and Primary Care Physicians Critical for Providing Effective Survivorship Care
By
Phoebe Starr
Survivorship Care
August 2022, Vol 13, No 4 Online Only
The number of cancer survivors continues to increase in the United States, which can be attributed to a growing and aging population, as well as recent advances in diagnosis and treatment. The Institute of Medicine advises that every cancer survivor receive a survivorship care plan summarizing his or her diagnosis, treatment, and recommendations regarding follow-up care.
Read More
Olaparib plus Abiraterone Combination Significantly Improves Radiographic PFS in Men with Metastatic Castration-Resistant Prostate Cancer
By
Phoebe Starr
Genitourinary Cancers
August 2022, Vol 13, No 4 Online Only
Combining the PARP inhibitor olaparib (Lynparza) with abiraterone acetate (Zytiga) led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (PFS) versus abiraterone alone in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair (HRR) status, according to results of the phase 3 PROpel trial.
Read More
Niraparib plus Abiraterone Combination Extends PFS in Men with CRPC and HRR Gene Mutations
By
Phoebe Starr
Prostate Cancer
August 2022, Vol 13, No 4 Online Only
The addition of the PARP inhibitor niraparib (Zejula) to abiraterone acetate (Zytiga) plus prednisone (AAP) led to a significant improvement in radiographic progression-free survival (PFS) versus AAP alone in men with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations, according to the final analysis of the primary end point of a phase 3 trial.
Read More
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma